Orthocell Ltd (AU:OCC) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Orthocell Limited, a regenerative medicine company, has retracted its revenue projections for a 20% market share of its products Remplir™ and Striate+™, initially presented in a recent company presentation. The Perth-based firm, which develops medical devices for bone and soft tissue injuries, has advised investors to disregard the previous financial estimates due to lack of a reasonable basis for such forecasts. Orthocell continues to focus on global market expansion and product development in the field of regenerative medicine.
For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.